finance.yahoo.comNOV 42 min read$ALMR

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

Original reporting

finance.yahoo.com

Published Nov 4, 2026, 5:10 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 4, 2026, 5:32 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · finance.yahoo.com

Decision brief

The 30-second read

$ALMRBullishMed

Why it matters

The earnings beat and raised guidance provide fresh data for valuation models and may trigger short‑covering.

Market read

First disclosure of earnings and guidance for ALMR; material for traders focused on biotech instrumentation.

What to watch

Cash burn remains high and TAP revenue is expected to decline sequentially, posing near‑term risk.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Alamar Biosciences reported its Q3 2026 earnings, highlighting a 68% revenue increase and new partnerships with UK Biobank and GSK.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ALMRBullishHigh confidence

Context

Q3 2026 earnings call disclosed 68% YoY revenue growth, record gross margin, and raised full-year revenue guidance to $121-123M.

Expected impact

likely upward pressure as market prices in the revenue beat and guidance raise

Evidence & confidence

Strong top-line growth and guidance lift for a cash‑rich company typically drive buying interest.

Market effects

Sector

Highlights growth potential in the biotech instrumentation and consumables market, may benefit peers with similar platforms.

Regional

U.S. biotech sector could see modest uplift.

Global

Limited to niche diagnostic instrument space.

Counterpoint

What could challenge this read

Higher operating losses and uncertain Q4 placement could temper enthusiasm; investors may wait for Q4 results.

Key entities

company
Alamar Biosciences Inc
Biotech diagnostics firm reporting Q3 earnings.

Read at source ← All news

NOV 4

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

finance.yahoo.com2 min

NOV 3

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

investing.com2 min

NOV 3

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o

SEC EDGAR 8-K2 min

OCT 29

$ALMRLow

Alamar Biosciences' Protein Signature Detects ALS With 98.3% Accuracy In Study

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA tech to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, involved 632 ALS patients and 160 healthy controls for development, and 144 ALS patients and 37 healthy controls for validation. The signature outperformed the established NFL biomarker. ALMR's stock closed at $34.30, up 7.42%, and was at $34.15 in overnight trading.

rttnews.com2 min

OCT 28

$ALMRMedAI 8/10

Alamar Biosciences’ technology used in study detecting ALS with 98% accuracy

Alamar Biosciences (ALMR) reported that Emory University researchers used its NULISA technology to identify a 10-protein blood signature with 98.3% accuracy in detecting ALS. The study, published in Nature Communications, measured over 300 proteins, though the signature is not yet clinically validated. CEO Yuling Luo emphasized the importance of measuring low-abundance proteins.

tipranks.com1 min

AUG 18